The expectations surrounding the industry’s rapid response to the COVID-19 pandemic required a change in perception across all of biopharma: every party involved in creating and developing COVID-19 assets had to find ways to accelerate therapy without sacrificing quality, safety and public trust.
In this article, we explore how COVID-19 drug development demands a more fully integrated and holistic solution that transcends the tactical and transactional to provide emerging COVID-19 treatment developers a powerful combination of asset strategy and execution.
